Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Letters to the Editor   |    
Response to Grant et al. Letter
Herbert D. Kleber, M.D.; Robert L. DuPont, M.D.
Am J Psychiatry 2012;169:1120-1120. doi:10.1176/appi.ajp.2012.12060791r
View Author and Article Information

The authors’ disclosures accompany the original commentary.

New York
Rockville, Md.

Accepted July , 2012.

text A A A

To the Editor: While we did not mention the Center for Medicinal Cannabis Research at the University of California, ably headed by Dr. Grant for the past decade, we did not suggest that the “evidence for marijuana’s efficacy is anecdotal”—just the large majority of it! We did say that “indications with the most evidence include spasticity secondary to neurological diseases such as multiple sclerosis (and) pain management, especially neuropathic pain.” These in fact are the subject of the references cited by Grant et al. to prove their point about marijuana efficacy. These also are the relatively rare conditions that most applicants claim as the reason they need medical marijuana cards, and less than 3% of applicants claim such conditions.

Finally, as we noted in our commentary, in 2011 daily marijuana use among high school seniors reached the highest level in 30 years, according to the Monitoring the Future survey conducted annually by researchers at the Institute for Social Research at the University of Michigan. Researchers found, as we pointed out, that “the rate of marijuana use in youths is inversely related to ‘perceived risk’ and ‘perceived social disapproval.’” Surely Grant et al. are not suggesting that the “medical marijuana” referenda and the dispensaries are unrelated to this increase.

We commend Grant et al. for their attempt to evaluate marijuana scientifically and look forward to the day when there will be FDA submissions.




CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 12.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 66.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 15.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 66.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 26.  >
Psychiatric News
PubMed Articles